The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Beam Therapeutics Inc. (BEAM) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.72, or 2.86%, to $25.87. The Beam Therapeutics Inc. has recorded 21,030 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Beam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT) Deficiency Disease-Causing Mutation.
Beam Therapeutics Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Beam Therapeutics Inc. is $1.97B. A total of 1.05 million shares were traded on the day, compared to an average of 823.56K shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, BEAM has seen 3 BUY and 3 SELL insider trades, representing the acquisition of 92,490 and the disposition of 156,921 shares. Over the last 12 months, there were 22 BUYs and 34 SELLs from insiders. Insiders purchased 431,499 shares during that period but sold 454,507.
In the most recent transaction, Ciaramella Giuseppe sold 1,206 shares of BEAM for 32.01 per share on Jul 24. After the transaction, the President and CSO now owns 48,250 company shares. In a previous transaction on Jul 21, Ciaramella Giuseppe sold 155,324 shares at 32.06 per share. BEAM shares that President and CSO owns now total 48,250.
Among the insiders who sold shares, Simon Amy disposed of 391 shares on Jul 10 at a per-share price of $30.48. This resulted in the Chief Medical Officer holding 68,917 shares of BEAM after the transaction. In another insider transaction, Simon Amy sold 11,654 shares at $29.70 per share on Apr 04. Company shares held by the Chief Medical Officer now total 69,308.
It is more appealing for investors to invest in companies that pay dividends because dividends generate immediate cash flow and indicate a positive outlook for the company. BEAM’s most recent ex-dividend date was 2/4/2014 when it declared a $0.2250 quarterly dividend that was paid in cash on 3/3/2014. Previously, the company paid the dividend on 12/2/2013 with an ex-dividend date of 11/4/2013. The BEAM stock dividend was $0.2250 per share in cash.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for BEAM in the last 3 months, the mean price target is $63.40 with high estimates of $105.00 and low estimates of $32.00. In terms of 52-week highs and lows, BEAM has a high of $61.40 and a low of $22.70.
As of this writing, BEAM has an earnings estimate of -$1.34 per share for the current quarter. EPS was calculated based on a consensus of 13 estimates, with a high estimate of -$1.13 per share and a lower estimate of -$1.62. The company reported an EPS of -$1.33 in the last quarter, which was 0.70% higher than expectations of -$1.34.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. BEAM’s latest balance sheet shows that the firm has $965.65M in Cash & Short Term Investments as of fiscal 2021. There were $142.35M in debt and $213.44M in liabilities at the time. Its Book Value Per Share was $10.63, while its Total Shareholder’s Equity was $826.74M.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BEAM is Buy with a score of 4.43.